Fractionation and late rectal toxicity

International Journal of Radiation Oncology Biology Physics

Volumn 60, Issue 4, 2004, Pages 1013-1015

  Brenner, David J ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RADIOTHERAPY; DOSE CALCULATION; DOSE RESPONSE; EDITORIAL; FRACTIONATION; HISTOGRAM; HUMAN; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROSTATE; QUANTITATIVE ANALYSIS; RADIATION DOSE; RECTUM DISEASE; RECTUM HEMORRHAGE; RECTUM INJURY; RISK ASSESSMENT; STANDARD; SURVIVAL; TOXICITY; UTERINE CERVIX CANCER;

DOSE FRACTIONATION; GASTROINTESTINAL HEMORRHAGE; HUMANS; LINEAR MODELS; MALE; PROSTATIC NEOPLASMS; RECTAL DISEASES;

EID: 7444265874     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.04.014     Document Type: Editorial

References (42)

1. Schultheiss T.E., Lee W.R., Hunt M.A., et al. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 37:1997;3-11
2. Skwarchuk M.W., Jackson A., Zelefsky M.J., et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I) Multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys. 47:2000;103-113
3. Ryu J.K., Winter K., Michalski J.M., et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys. 54:2002;1036-1046
4. Michalski J.M., Winter K., Purdy J.A., et al. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. Int J Radiat Oncol Biol Phys. 56:2003;192-198
5. Kuban D., Pollack A., Huang E., et al. Hazards of dose escalation in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 57:2003;1260-1268
6. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 53:2002;1111-1116
7. Clark B.G., Souhami L., Roman T.N., et al. The prediction of late rectal complications in patients treated with high dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 38:1997;989-993
8. Leborgne F., Fowler J.F., Leborgne J.H., et al. Biologically effective doses in medium dose rate brachytherapy of cancer of the cervix. Radiat Oncol Invest. 5:1997;289-299
9. Chun M., Kang S., Kil H.J., et al. Rectal bleeding and its management after irradiation for uterine cervical cancer. Int J Radiat Oncol Biol Phys. 58:2004;98-105
10. Wang C.J., Leung S.W., Chen H.C., et al. The correlation of acute toxicity and late rectal injury in radiotherapy for cervical carcinoma Evidence suggestive of consequential late effect (CQLE). Int J Radiat Oncol Biol Phys. 40:1998;85-91
11. Dorr W., Hendry J.H. Consequential late effects in normal tissues. Radiother Oncol. 61:2001;223-231
12. Jereczek-Fossa B.A., Jassem J., Badzio A. Relationship between acute and late normal tissue injury after postoperative radiotherapy in endometrial cancer. Int J Radiat Oncol Biol Phys. 52:2002;476-482
13. Terry N.H., Denekamp J. RBE values and repair characteristics for colo-rectal injury after caesium-137 gamma-ray and neutron irradiation. II. Fractionation up to ten doses. Br J Radiol. 57:1984;617-629
14. van der Kogel A.J., Jarrett K.A., Paciotti M.A., et al. Radiation tolerance of the rat rectum to fractionated X-rays and pi-mesons. Radiother Oncol. 12:1988;225-232
15. Dewit L., Oussoren Y., Bartelink H., et al. The effect of cis-diamminedichloroplatinum(II) on radiation damage in mouse rectum after fractionated irradiation. Radiother Oncol. 16:1989;121-128
16. Gasinska A., Dubray B., Hill S.A., et al. Early and late injuries in mouse rectum after fractionated X-ray and neutron irradiation. Radiother Oncol. 26:1993;244-253
17. Dubray B.M., Thames H.D. Chronic radiation damage in the rat rectum An analysis of the influences of fractionation, time and volume. Radiother Oncol. 33:1994;41-47
18. Brenner D., Armour E., Corry P., et al. Sublethal damage repair times for a late-responding tissue relevant to brachytherapy (and external-beam radiotherapy) Implications for new brachytherapy protocols. Int J Radiat Oncol Biol Phys. 41:1998;135-138
19. van den Aardweg G.J., Olofsen-van Acht M.J., van Hooije C.M., et al. Radiation-induced rectal complications are not influenced by age A dose fractionation study in the rat. Radiat Res. 159:2003;642-650
20. Brenner D.J. Hypofractionation for prostate cancer radiotherapy - what are the issues? Int J Radiat Oncol Biol Phys. 57:2003;912-914
21. Duchesne G.M., Peters L.J. What is the α/β ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 44:1999;747-748
22. Akimoto T, Muramatsu H, Takahashi M, et al. Rectal bleeding after hypofractionated radiotherapy for prostate cancer: Correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding. Int J Radiat Biol Oncol Phys 2004; 60:1033-1039
23. Hall E.J., Schiff P.B., Hanks G.E., et al. A preliminary report Frequency of A-T heterozygotes among prostate cancer patients with severe late responses to radiation therapy. Cancer J Sci Am. 4:1998;385-389
24. Herold D.M., Hanlon A.L., Hanks G.E. Diabetes mellitus A predictor for late radiation morbidity. Int J Radiat Oncol Biol Phys. 43:1999;475-479
25. Chism D.B., Horwitz E.M., Hanlon A.L., et al. Late morbidity profiles in prostate cancer patients treated to 79-84 Gy by a simple four-field coplanar beam arrangement. Int J Radiat Oncol Biol Phys. 55:2003;71-77
26. Bey P., Carrie C., Beckendorf V., et al. Dose escalation with 3D-CRT in prostate cancer French study of dose escalation with conformal 3D radiotherapy in prostate cancer - preliminary results. Int J Radiat Oncol Biol Phys. 48:2000;513-517
27. Dearnaley D.P., Khoo V.S., Norman A.R., et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer A randomised trial. Lancet. 353:1999;267-272
28. Kneebone A., Turner S., Berry M., et al. Australian prostate-specific antigen outcome and toxicity following radiation therapy for localized prostate cancer. Australas Radiol. 47:2003;422-427
29. Livsey J.E., Cowan R.A., Wylie J.P., et al. Hypofractionated conformal radiotherapy in carcinoma of the prostate Five-year outcome analysis. Int J Radiat Oncol Biol Phys. 57:2003;1254-1259
30. King H., Aubert R.E., Herman W.H. Global burden of diabetes, 1995-2025 Prevalence, numerical estimates, and projections. Diabetes Care. 21:1998;1414-1431
31. Thames HD, Hendry JH. Fractionation in radiotherapy. London; New York: Taylor & Francis; 1987. p. 27-29
32. Green P.J. Iteratively reweighted least-squares for maximum-likelihood estimation, and some robust and resistant alternatives. J Roy Stat Soc B Meth. 46:1984;149-192
33. Press WH, Flannery BF, Teukolsky SA, et al. Numerical recipes: The art of scientific computing. Cambridge: Cambridge University Press; 1986. p. 529-532
34. Brenner D.J., Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 43:1999;1095-1101
35. Fowler J.F., Chappell R.J., Ritter M.A. Is α/β for prostate tumors really low? Int J Radiat Oncol Biol Phys. 50:2001;1021-1031
36. King C.R., Fowler J.F. A simple analytic derivation suggests that prostate cancer α/β ratio is low. Int J Radiat Oncol Biol Phys. 51:2001;213-214
37. Dale RG, Jones B. Is the α/β for prostate tumors really low? In regard to Fowler, et al., IJROBP 2001;50:1021-1031. Int J Radiat Oncol Biol Phys 2002;52:1427-1428
38. Dale RG, Jones B. Is the α/β for prostate tumors really low? In regard to Fowler, et al., IJROBP 2001;50:1021-1031. Int J Radiat Oncol Biol Phys 2002;52:1427-1428
39. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 52:2002;6-13
40. Kal HB, Van Gellekom MPR. How low is the α/β ratio for prostate cancer? Int J Radiat Oncol Biol Phys 2003;57:1116-1121
41. Wang J.Z., Li X.A., Yu C.X., et al. The low alpha/beta ratio for prostate cancer What does the clinical outcome of HDR brachytherapy tell us? Int J Radiat Oncol Biol Phys. 57:2003;1101-1108
42. D'Souza W.D., Thames H.D. Is the α/β ratio for prostate cancer low? Int J Radiat Oncol Biol Phys. 51:2001;1-3